MY204827A - Semaglutide in medical therapy - Google Patents
Semaglutide in medical therapyInfo
- Publication number
- MY204827A MY204827A MYPI2020001658A MYPI2020001658A MY204827A MY 204827 A MY204827 A MY 204827A MY PI2020001658 A MYPI2020001658 A MY PI2020001658A MY PI2020001658 A MYPI2020001658 A MY PI2020001658A MY 204827 A MY204827 A MY 204827A
- Authority
- MY
- Malaysia
- Prior art keywords
- semaglutide
- medical therapy
- medicament
- subject
- need
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY204827A true MY204827A (en) | 2024-09-18 |
Family
ID=60083831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020001658A MY204827A (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US12029779B2 (enExample) |
| EP (1) | EP3694538A1 (enExample) |
| JP (2) | JP7148605B2 (enExample) |
| KR (1) | KR20200069316A (enExample) |
| CN (4) | CN120241968A (enExample) |
| AU (2) | AU2018348929B2 (enExample) |
| BR (1) | BR112020006246A2 (enExample) |
| CA (1) | CA3078652A1 (enExample) |
| CL (1) | CL2020000812A1 (enExample) |
| IL (3) | IL322969A (enExample) |
| MA (1) | MA50358A (enExample) |
| MX (3) | MX2020003049A (enExample) |
| MY (1) | MY204827A (enExample) |
| PH (1) | PH12020550185A1 (enExample) |
| SG (1) | SG11202002841PA (enExample) |
| TW (1) | TWI842681B (enExample) |
| WO (1) | WO2019072941A1 (enExample) |
| ZA (3) | ZA202503388B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322969A (en) * | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
| WO2021162532A2 (ko) | 2020-02-14 | 2021-08-19 | 주식회사 지투지바이오 | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 |
| PE20221575A1 (es) * | 2020-02-18 | 2022-10-06 | Novo Nordisk As | Formulaciones farmaceuticas |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| EP4313016A4 (en) * | 2021-03-29 | 2025-01-22 | Sanford Health | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| EP4536691A1 (en) * | 2022-06-08 | 2025-04-16 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| WO2024249659A2 (en) * | 2023-05-30 | 2024-12-05 | The Medical College Of Wisconsin, Inc. | Methods for weight loss and/or reducing weight gain |
| WO2024252134A1 (en) * | 2023-06-05 | 2024-12-12 | Closed Loop Medicine Ltd | Dosing of incretin pathway drugs |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US20030119734A1 (en) | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| PT1687019T (pt) | 2003-11-20 | 2018-02-26 | Novo Nordisk As | Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção |
| EP2494983B1 (en) | 2004-11-12 | 2019-04-24 | Novo Nordisk A/S | Stable formulations of glp-1 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| WO2007121411A2 (en) | 2006-04-14 | 2007-10-25 | Mannkind Corporation | Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
| CN101631548B (zh) | 2007-01-31 | 2014-08-27 | 比艾尔-坡特拉有限公司 | Comt抑制剂的单次药物剂量单元和药物组合物 |
| US20100047762A1 (en) | 2007-03-20 | 2010-02-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| DK2373681T3 (en) | 2008-12-10 | 2017-04-24 | Glaxosmithkline Llc | PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID |
| NZ619520A (en) | 2009-02-13 | 2015-06-26 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| CA2784757A1 (en) | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
| CA2822617A1 (en) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| WO2012177929A2 (en) | 2011-06-24 | 2012-12-27 | Amylin Pharmaceuticals, Inc. | Methods for treating diabetes with extended release formulations of glp-1 receptor agonists |
| JP6280501B2 (ja) | 2011-09-08 | 2018-02-14 | メレオ バイオファーマ ２ リミテッド | 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用 |
| EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| CA3067012C (en) | 2012-06-29 | 2021-10-05 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| RS67258B1 (sr) | 2012-07-01 | 2025-10-31 | Novo Nordisk As | Upotreba dugodelujućih glp-1 peptida |
| KR20210086717A (ko) * | 2013-05-02 | 2021-07-08 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| CR20180378A (es) | 2015-12-23 | 2018-12-06 | Amgen Inc | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1 |
| US10813918B2 (en) | 2017-08-04 | 2020-10-27 | Ovid Therapeutics Inc. | Use of Gaboxadol in the treatment of diabetes and related conditions |
| IL322969A (en) | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
-
2018
- 2018-10-10 IL IL322969A patent/IL322969A/en unknown
- 2018-10-10 CN CN202510086779.1A patent/CN120241968A/zh active Pending
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt not_active Application Discontinuation
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh not_active Withdrawn
- 2018-10-10 CN CN202510084667.2A patent/CN119838000A/zh active Pending
- 2018-10-10 IL IL322968A patent/IL322968A/en unknown
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko active Pending
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-10 CN CN202411858188.3A patent/CN119950682A/zh active Pending
- 2018-10-10 AU AU2018348929A patent/AU2018348929B2/en active Active
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 MY MYPI2020001658A patent/MY204827A/en unknown
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en not_active Ceased
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-19 MX MX2025002188A patent/MX2025002188A/es unknown
- 2020-03-19 MX MX2025002189A patent/MX2025002189A/es unknown
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en not_active Abandoned
- 2024-08-30 US US18/820,792 patent/US12295988B2/en active Active
-
2025
- 2025-04-09 US US19/174,121 patent/US12551536B2/en active Active
- 2025-04-22 ZA ZA2025/03388A patent/ZA202503388B/en unknown
- 2025-04-22 ZA ZA2025/03350A patent/ZA202503350B/en unknown
- 2025-04-22 ZA ZA2025/03387A patent/ZA202503387B/en unknown
- 2025-05-15 AU AU2025203535A patent/AU2025203535A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| PH12020550185A1 (en) | Semaglutide in medical therapy | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| TN2015000480A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| PH12015502655A1 (en) | Method | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
| PH12015500915A1 (en) | Bremelanotide therapy for female sexual dysfunction | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| MX2022002038A (es) | Composicion farmaceutica para el tratamiento del insomnio. | |
| MX2021003288A (es) | Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica. |